Poster Session 1-9 ALL: Treatment

[PS1-9-2] Phase 1b study of blinatumomab in Japanese adults with relapsed/refractory ALL

Yukio Kobayashi¹, Joan D Moris², Toru Sakura³, Catherine A Tuglus², Min Zhu², Toshihiro Miyamoto⁴, Hiroatsu Iida⁵ (1.National Cancer Center Hospital and International University of Health and Welfare, Mita Hospital, Tokyo, Japan, 2.Amgen Inc., Thousand Oaks, United States of America, 3.Leukemia Research Center, Maebashi, Japan, 4.Kyushu University Graduate School of Medical Science, Fukuoka, Japan, 5.National Hospital Organization Nagoya Medical Center, Nagoya, Japan)